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A 38-year-old woman was admitted to the emer-
gency unit with chest pain radiating to her left
arm. She had recently suffered from a cold with
cough and neck pain lasting for 2 weeks. The pa-
tient had a history of deep venous thrombosis
during pregnancy associated with APC-resis-
tance. She had neither cardiovascular risk factors
nor a history of coronary or cerebral artery dis-
ease. The family history was negative for coro-
nary heart disease and stroke.
On admission the patient complained of
strong pain in the left side of the chest worsening
on inspiration. She had painful musculoskeletal
points on the left chest wall and neck, otherwise
physical examination was normal. Computed to-
mography of the chest ruled out pulmonary em-
bolism. Neither electrocardiogram nor echocar-
diography showed any evidence of perimyocardi-
tis, myocardial ischaemia or cardiac infarction.
However, elevated troponin T serum levels (1.76
mg/l) were detected (Elecsys E170, Roche Diag-
nostic, Rotkreuz, Switzerland), while CK (90
U/l, Modular P, Roche Diagnostic), CK-MB (13
U/l, Modular P, Roche Diagnostic), and myoglo-
bin (29 U/l, Elecsys E170, Roche Diagnostic)
were within reference ranges.
Repeat measurements showed that serum
concentration of troponin T remained elevated
(1.65 mg/l, 1.46 mg/l and 1.75 mg/l after two, six
and 48 hours, respectively) while levels of CK,
CK-MB, and myoglobin remained within their
reference ranges.
In view of the persistently elevated serum
concentrations of troponin T without elevation
of other cardiac necrosis markers, we decided not
to undertake coronary angiography suspecting
interference of heterophilic antibodies with the
troponin T assay. To show such interference, we
treated a serum sample of our patient with het-
erophilic blocking reagent (Scantibodies Labora-
tory, Santee, CA, USA) for one hour and meas-
ured troponin T again. The troponin T level de-
creased to 0.18 mg/l upon treatment with the
blocking antibody while the same treatment did
not alter the troponin T level in a sample from a
patient with acute coronary syndrome measured
in parallel. These results confirmed antibody in-
terference in the troponin assay. The patient was
discharged with the diagnosis of musculoskeletal
chest pain.
The origin of the heterophilic antibodies is
not clear. However, in a recent review Levinson
and Miller argued that they represent natural an-
tibodies that bind their antigen with low affinity
[1]. This may explain why the older radioim-
munoassay that depend on strong affinity bind-
ing of the antibodies were less prone to such in-
teractions than the newer generation immunoas-
says [1]. These modern immunoassays have been
revised by adding non-specific blocking antibod-
ies to the assay to reduce the effect of interfering
antibodies [2], however, some patients may ex-
ceed the blocking capacity of a specific im-
munoassay procedure [3, 4].
It is estimated that heterophilic antibodies
cause about one false result in every 2000 investi-
gations produced with modern immunoassays
[1]. This can result in unnecessary and possibly
even harmful diagnostic procedures and/or treat-
ment. Therefore, physicians need to be aware of
these interferences with immunoassays, which
basically can occur with every immunoassay.
Contacting their laboratory directors will allow
testing for the presence of such heterophilic anti-
bodies in a patient’s sample. The suspected sam-
ple can be re-measured with an assay from an-
other manufacturer and will usually give a dis-
cordant result, at least when assayed by a differ-
ent two-site method [1]. Alternatively, the sample
can be re-analyzed after pre-treatment with
commercially available heterophilic blocking
reagents, as presented in this report [5, 6].
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